• Vaccine Name: split-conjugated animal brucellosis vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009461
• Type: Inactivated vaccine
• Status: Research
• Host Species for Licensed Use: Cattle
• Adjuvant: fosprenil
• Preparation: The dry split-conjugated vaccine was dissolved in saline; fosprenil was administered intramuscularly; polypeptide C was mixed with the vaccine for subcutaneous injection in one group; another group received vaccine diluted with isotonic sodium chloride solution. (Bouchemla et al, 2019)
• Description: The study aimed to obtain a vaccine against animal brucellosis with high immunogenic properties by evaluating the effectiveness of a split-conjugated vaccine combined with immunomodulators fosprenil and polypeptide C. Efficacy: The split-conjugated vaccine combined with fosprenil induced higher antibody titers that persisted longer compared to the vaccine combined with polypeptide C or vaccine alone. Immune response: The vaccine with fosprenil enhanced the humoral immune response against brucellosis in calves. (Bouchemla et al, 2019)

Cattle Response

• Vaccination Protocol: Eighteen Holstein Friesian calves were divided into three groups receiving different vaccine and immunomodulator combinations; serological tests (agglutination reaction, complement fixation, rose Bengal test) were performed on days 14, 30, and 90 post-vaccination. (Bouchemla et al, 2019)
• Immune Response: The vaccine with fosprenil enhanced the humoral immune response against brucellosis in calves. (Bouchemla et al, 2019)
• Efficacy: The split-conjugated vaccine combined with fosprenil induced higher antibody titers that persisted longer compared to the vaccine combined with polypeptide C or vaccine alone. (Bouchemla et al, 2019)
• Description: Eighteen Holstein Friesian calves were divided into three groups receiving different vaccine and immunomodulator combinations; serological tests (agglutination reaction, complement fixation, rose Bengal test) were performed on days 14, 30, and 90 post-vaccination. (Bouchemla et al, 2019)